ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA techno…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases. | ||
 Arcturus Highlights ARCT-810 Phase II Data, Unveils Next-Gen OTC Therapy Platform Arcturus Therapeutics (NASDAQ:ARCT) presented preliminary Phase II data for ARCT-810, its mRNA therapeutic candidate for ornithine transcarbamylase, or OTC, deficiency, while outlining plans to introduce a next-generation delivery platform into the program. OTC deficiency is a urea-cycle disorder i | ||
Sector Update: Healthcare Stocks Advance Late Afternoon Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9 | ||
 CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls | ||
 Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? Is it a good or bad thing when a stock experiences a golden cross technical event? | ||
 Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers | ||
 Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse? Moderna and Merck scored a big win for their cancer vaccine on Wednesday. But analysts say it's too early to call it a home run. | ||
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana | ||
 Arcturus Therapeutics Q2 Earnings Call Highlights Arcturus Therapeutics (NASDAQ:ARCT) reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA | ||
 Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Exelixis (EXEL) Tops Q2 Earnings Estimates Exelixis (EXEL) delivered earnings and revenue surprises of +5.81% and -0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||